Thilak Chander
Internal Medicine · Sault Sainte Marie, MINPI 1760698484
Payments from drug & device makers
Across 341 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$828
- Novo Nordisk$672
- Johnson & Johnson$345
- Merck$343
- Boehringer Ingelheim$336
- GSK$336
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,04998%
- Education$1142%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $828 |
| Novo Nordisk | 49 | $672 |
| Johnson & Johnson | 30 | $345 |
| Merck | 21 | $343 |
| Boehringer Ingelheim | 21 | $336 |
| GSK | 28 | $336 |
| Sanofi-aventis U.S. LLC | 19 | $335 |
| Grifols USA, LLC | 17 | $306 |
| Novartis | 18 | $284 |
| Pfizer | 16 | $268 |
| Amgen(2 entities) | 12 | $226 |
| Astellas Pharma US Inc | 6 | $183 |
| Lilly USA, LLC | 9 | $145 |
| Esperion Therapeutics, Inc. | 6 | $108 |
| Sunovion Pharmaceuticals Inc. | 18 | $102 |
| Amarin Pharma, Inc. | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $60 |
| Biohaven Pharmaceuticals, Inc. | 2 | $42 |
| Radius Health, Inc. | 3 | $40 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Dexcom, Inc. | 2 | $32 |
| Medtronic | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Bayer | 1 | $13 |
How this compares
$5,163 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 173 | $204,045 |
| XareltoRivaroxaban | 143 | $140,306 |
| OzempicSemaglutide | 87 | $129,012 |
| FarxigaDapagliflozin Propanediol | 95 | $117,137 |
| JardianceEmpagliflozin | 70 | $91,948 |
| TrulicityDulaglutide | 34 | $46,426 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 48 | $35,871 |
| RybelsusSemaglutide | 25 | $30,901 |
| EntrestoSacubitril/Valsartan | 16 | $29,695 |
| MyrbetriqMirabegron | 32 | $29,186 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $20,188 |
| Breo ElliptaFluticasone/Vilanterol | 27 | $16,235 |
| Repatha SureclickEvolocumab | 20 | $16,168 |
| Telmisartan | 224 | $13,173 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $12,714 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $268 | $204,045173 claims |
| Novo NordiskOzempic, Rybelsus | $672 | $159,913112 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $828 | $143,820141 claims |
| Johnson & JohnsonXarelto | $345 | $140,306143 claims |
| Boehringer IngelheimJardiance | $336 | $91,94870 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $336 | $64,82095 claims |
| Lilly USA, LLCTrulicity | $145 | $46,42634 claims |
| NovartisEntresto | $284 | $29,69516 claims |
| Astellas Pharma US IncMyrbetriq | $183 | $29,18632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Sault Sainte Marie
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Abdulhassan SaadDearborn$11.5M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
- Sudipto MukherjeeRoyal Oak$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.